Abstract | AIMS: METHODS: Two randomized, double-blind, placebo-controlled, phase 1 studies of oral TAK-418 were performed, a first-in-human single-rising-dose (SRD) study (5-60 mg) in healthy adult male and female volunteers (placebo, n = 10; TAK-418, n = 30), and an SRD (120-160 mg) and multiple-rising-dose (MRD) study (20-160 mg once daily for 10 days) in healthy female volunteers (placebo, n = 2 [SRD] and n = 6 [MRD]; TAK-418, n = 6 [SRD] and n = 18 [MRD]). RESULTS:
TAK-418 was well tolerated. No clinically significant changes in laboratory test results or vital signs were observed and no serious adverse events were reported. TAK-418 had a nearly linear pharmacokinetic profile, with rapid absorption and short terminal half-life across the evaluated dose range. No obvious accumulation was observed after daily administration for 10 days. Administration with food delayed peak plasma concentrations but overall exposure was unaffected. TAK-418 rapidly crossed the blood-brain barrier and generally showed a dose-dependent response in the peripheral pharmacodynamic biomarker formyl- flavin adenine dinucleotide. CONCLUSION: The brain-penetrant LSD1 inhibitor TAK-418 was well tolerated, with pharmacokinetic and pharmacodynamic effects that support further investigation.
|
Authors | Wei Yin, Dimitrios Arkilo, Polyna Khudyakov, Jim Hazel, Saurabh Gupta, Maria S Quinton, Jie Lin, Deborah S Hartman, Martin M Bednar, Laura Rosen, Jens R Wendland |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 87
Issue 12
Pg. 4756-4768
(12 2021)
ISSN: 1365-2125 [Electronic] England |
PMID | 33990969
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 Takenda Inc. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. |
Chemical References |
|
Topics |
- Area Under Curve
- Dose-Response Relationship, Drug
- Double-Blind Method
- Epigenesis, Genetic
- Female
- Humans
- Lysine
- Male
|